FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. Pete O'Heeron, Founder and CEO, will represent the company.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents. Their presentation will be available on-demand to registered attendees starting September 9, 2024, at 7 a.m. Eastern Time.
Interested parties can find more information on FibroBiologics' website or by contacting info@fibrobiologics.com.
Details
News Market Reaction – FBLG
The recorded move for FBLG in the trading session of this news was +12.37%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11 at the Lotte New York Palace Hotel in New York City.
FibroBiologics’ presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 9, 2024, at 7 a.m. Eastern Time.
For more information, please visit FibroBiologics' website or email FibroBiologics at info@fibrobiologics.com.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.